Table 2.

In vitro activities of BMS-207147, Sch56592, and voriconazole against isolates of Candida species with decreased susceptibility to fluconazole and itraconazole

Species (no. of isolates) and antifungal agentMIC (μg/ml)
Range50% of isolates90% of isolates
C. albicans(12)
 BMS-2071470.03–>8.00.12>8
 Sch 565920.03–>8.08.0>8.0
 Voriconazole0.25–>8.0>8.0>8.0
 Fluconazole64–>128>128>128
 Itraconazole1.0–>8.0>8.0>8.0
C. glabrata (25)
 BMS-2071470.5–>8.04.08.0
 Sch 565921.0–>84.0>8.0
 Voriconazole1.0–8.04.08.0
 Fluconazole64–>128128>128
 Itraconazole2.0–>8.0>8.0>8.0
C. krusei (13)
 BMS-2071470.25–0.50.250.5
 Sch 565920.25–1.00.50.5
 Voriconazole0.25–1.00.51.0
 Fluconazole64–12864128
 Itraconazole1.0–2.01.02.0
C. tropicalis(3)
 BMS-207147>8.0>8.0
 Sch 565928–>8.0>8.0
 Voriconazole4–>8.0>8.0
 Fluconazole128–>128>128
 Itraconazole>8.0>8.0